2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Mean (Range) (2010–2019) | |
---|---|---|---|---|---|---|---|---|---|---|---|
(n = 4909) | (n = 7256) | (n = 7993) | (n = 7278) | (n = 8023) | (n = 9057) | (n = 9176) | (n = 9225) | (n = 9102) | (n = 9335) | ||
Number of treated patients with b/tsDMARDs and number of patients with double or multiple b/tsDMARDs registration errors (RE) | |||||||||||
b/tsDMARD users, N | 1936 | 2855 | 3136 | 3060 | 3419 | 3688 | 3770 | 3869 | 3869 | 4158 | |
b/tsDMARD RE, N [%] | 23 [1.2] | 27 [0.9] | 23 [0.7] | 28 [0.9] | 29 [0.8] | 45 [1.2] | 139 [3.7] | 96 [2.5] | 54 [1.4] | 51 [1.2] | 1.5% (0.7–3.7%) |
Number of registered b/tsDMARDs (Percentage of n) [Percentage of the corresponding medication group] | |||||||||||
b/tsDMARDs (%) | 1959 (40) | 2882 (40) | 3159 (40) | 3088 (42) | 3448 (43) | 3733 (41) | 3909 (43) | 3965 (43) | 3923 (43) | 4209 (45) | 42% (40–45%) |
TNFi [%] | 1485 [76] | 2134 [74] | 2319 [73] | 2262 [73] | 2469 [72] | 2544 [68] | 2696 [69] | 2668 [67] | 2462 [63] | 2689 [64] | 70% (64–76%) |
Non-TNFi [%] | 474 [24] | 748 [26] | 840 [27] | 826 [27] | 979 [28] | 1189 [32] | 1213 [31] | 1262 [32] | 1183 [30] | 1084 [26] | 28% (24–32%) |
tsDMARD [%] | NA | NA | NA | NA | NA | NA | NA | 35 [0.9] | 278 [7.1] | 436 [10.4] | 6.1% (0.9–10%) |
Number of b/tsDMARD users treated with csDMARDs, Methotrexate, and Glucocorticoids (percentage of b/tsDMARD users) | |||||||||||
csDMARD, N (%) | 1430 (74) | 2086 (73) | 2256 (72) | 2208 (72) | 2415 (71) | 2596 (70) | 2630 (70) | 2676 (69) | 2568 (66) | 2706 (65) | 70% (65–74%) |
Methotrexate, N (%) | 1309 (68) | 1885 (66) | 2035 (65) | 1983 (65) | 2163 (63) | 2282 (62) | 2288 (61) | 2327 (60) | 2243 (58) | 2357 (57) | 62% (57–68%) |
Glucocorticoids, N (%) | 816 (42) | 1123 (39) | 1181 (38) | 1136 (37) | 1210 (35) | 1277 (35) | 1208 (32) | 1189 (31) | 1144 (30) | 1199 (29) | 35% (29–42%) |
Naïve Starting b/tsDMARD users vs. Non-Naïve starting b/tsDMARD users (percentage of starting b/tsDMARD users) [Percentage of the corresponding medication group] | |||||||||||
All starting b/tsDMARDs | 832 | 887 | 875 | 857 | 852 | 946 | 1671 | 1342 | 1068 | 1475 | |
Naïve to b/tsDMARDs | 378 (45) | 424 (48) | 421 (48) | 386 (45) | 356 (42) | 367 (39) | 400 (24) | 418 (31) | 408 (38) | 409 (28) | 39% (24–48%) |
Naïve to TNFi [%] | 326 [86] | 382 [90] | 384 [91] | 350 [91] | 310 [87] | 308 [84] | 362 [91] | 372 [89] | 327 [80] | 355 [87] | 88% (80–91%) |
Naïve to Non-TNFi [%] | 52 [14] | 42 [9.9] | 37 [8.8] | 36 [9.3] | 46 [13] | 59 [16] | 38 [9.5] | 46 [11] | 51 [13] | 23 [5.6] | 11% (5.6–16%) |
Naïve to tsDMARDs [%] | NA | NA | NA | NA | NA | NA | NA | NA | 30 [7.4] | 31 [7.6] | 7.5% (7.4–7.6%) |
Non-naïve to b/tsDMARDs | 454 (55) | 463 (52) | 454 (52) | 471 (55) | 496 (58) | 579 (61) | 1271 (76) | 924 (69) | 660 (62) | 1066 (72) | 61% (52–76%) |
TNFi [%] | 213 [50] | 252 [54] | 282 [62] | 281 [60] | 278 [56] | 364 [63] | 1053 [83] | 637 [69] | 337 [51] | 518 [49] | 60% (49–83%) |
Non-TNFi [%] | 241 [53] | 211 [46] | 172 [38] | 190 [40] | 218 [44] | 215 [37] | 218 [17] | 232 [25] | 133 [20] | 321 [30] | 35% (17–53%) |
tsDMARDs [%] | NA | NA | NA | NA | NA | NA | NA | 55 [6.0] | 190 [29] | 227 [21] | 19% (6.0–29%) |
The annual mean cost of b/tsDMARDs in thousand Euro [Adjusted consume price index price for 2010 NOK value] | |||||||||||
Current b/tsDMARD cost | 13.1 [13.1] | 10.6 [10.5] | 11.5 [11.1] | 10.8 [10.3] | 11.5 [10.7] | 10.5 [9.7] | 9.4 [8.3] | 9.6 [8.4] | 8.2 [7.1] | 6.9 [5.8] | |
Naïve b/tsDMARD cost | 13.0 [13.0] | 10.3 [10.2] | 11.0 [10.6] | 10.1 [9.6] | 9.1 [8.4] | 6.6 [6.1] | 6.4 [5.7] | 6.9 [6.0] | 5.3 [4.6] | 3.2 [2.7] | |
Non-Naïve b/tsDMARD cost | 12.9 [12.9] | 10.9 [10.7] | 11.7 [11.3] | 10.8 [10.3] | 10.5 [9.8] | 8.1 [7.5] | 7.6 [6.7] | 7.6 [6.7] | 5.9 [5.1] | 4.6 [3.9] | |
The annual total cost of b/tsDMARDs in Million Euro [Adjusted consume price index price for 2010 NOK value] | |||||||||||
Current b/tsDMARD cost | 25.6 [25.6] | 30.7 [30.3] | 36.4 [35.0] | 33.4 [31.7] | 39.6 [36.8] | 39.2 [36.1] | 36.6 [32.5] | 38.1 [33.3] | 32.3 [28.0] | 28.9 [24.4] | |
Naïve b/tsDMARD cost | 4.9 [4.9] | 4.4 [4.3] | 4.6 [4.5] | 3.9 [3.7] | 3.2 [3.0] | 2.4 [2.2] | 2.6 [2.3] | 2.9 [2.5] | 2.1 [1.9] | 1.3 [1.1] | |
Non-Naïve b/tsDMARD cost | 5.9 [5.9] | 5.0 [5.0] | 5.3 [5.1] | 5.1 [4.8] | 5.2 [4.8] | 4.7 [4.3] | 9.6 [8.5] | 7.1 [6.2] | 3.9 [3.4] | 4.9 [4.2] |